Compare stocks

BAX vs TMCI

vs

Baxter International Inc. and Treace Medical Concepts, Inc. Common Stock

Sources and methodology ↗

Compare any two stock symbols.

1 of 3 daily views used · 2 remaining. Refreshes and chart changes do not use another view.

Daily close · 2026-11-16

Price return

Both stocks start at 0% on the first shared trading day.

BAX-70.93%
TMCI-82.69%
Price return: BAX and TMCIHistorical recorded observations on the same scale. Missing metrics leave gaps.-106%-67%-27%13%52%202120222023202420252026

Use left and right arrow keys to inspect historical line observations. Financial bars can be focused individually.

Split-adjusted closing prices. Dividends are excluded.Year ranges begin January 1 of the end year minus the selected years.
Aurora
AURORA

Ask about these stocks.

CONTEXT ATTACHEDBAX + TMCIPrices, financials and SEC filing evidence

Uses research tokens · Agent runs can use more

Similarity
56.3%
3 shared / 6 total tags

How similar are their businesses?

The score compares business activities in annual filings released in 2025. Core activities receive four times the weight of material activities. Industries that fewer companies share carry more weight.

HealthcareMedical DevicesTechnology
How we measure overlap ↗
The businesses behind the score

Industry overlap

Filing-derived business activity overlapCounts of retained positive business classifications. Circle sizes do not encode the counts or the weighted similarity score.BAX only3Shared3TMCI only0

BAX only · 3

Shared activities · 3

TMCI only · 0

No activities in this group.

Positive activities from the two selected annual filings. Expand each group to view all its activities, or use the complete table below. These are classification sets, not revenue shares. The weighted similarity score also accounts for exposure and how common each activity is.
Show business activity table · 6 rows, 3 columns

Core activities receive full weight; material activities receive one quarter. Select a tag to read the filing evidence.

Business activityBAXTMCI
CoreCore
CoreCore
CoreMaterial
MaterialNot tagged
CoreNot tagged
MaterialNot tagged

Healthcare

BAX Core

Annual filing released 2025-02-21 · GPT 6 Luna

PART I Item 1. Business. Company Overview Baxter International Inc., through its subsidiaries, provides a broad portfolio of essential healthcare products, including sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices. These products are used by hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers and patients at home under physician supervision. Our global footprint and the critical nature of our products and services play a key role in expanding access to healthcare in emerging and developed countries.
Nature of Operations Baxter International Inc., through our subsidiaries (collectively, Baxter, we, our or us), provides a broad portfolio of essential healthcare products, including sterile intravenous (IV) solutions; infusion systems, administrative sets; parenteral nutrition therapies; surgical hemostat, sealant and adhesion prevention products; connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies; respiratory health devices; advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices and other accessories; injectable pharmaceuticals; inhaled anesthetics and drug compounding services.
Read the annual filing ↗

TMCI Core

Annual filing released 2025-02-27 · GPT 6 Luna

We are a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. We have pioneered and patented the Lapiplasty® 3D Bunion Correction System®—a combination of instruments, implants and surgical methods designed to surgically correct all three planes of the bunion deformity and address the root cause of the bunion, helping patients get back to their active lifestyles. To further support the needs of bunion patients, we have introduced our Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot.
Segments The Company is a single reportable segment entity, which is in the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. The Company's chief executive officer is the chief operating decision maker ("CODM"). The CODM regularly reviews entity-wide net income and operating results compared to budget and forecast information to assess the Company's performance and to allocate resources for its single reporting segment. The measure of profit or loss is reported in the Statement of Operations and Comprehensive Loss. The measure of segment assets is reported on the Company's Balance Sheet. The Company does not have any intra-entity sales or transfers. All long-lived assets are maintained in the United States.
Read the annual filing ↗

Medical Devices

BAX Core

Annual filing released 2025-02-21 · GPT 6 Luna

The Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including surgical video technologies, precision positioning devices and other accessories.
Healthcare Systems & Technologies Our Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including surgical video technologies, precision positioning devices and other accessories. Percent change years ended December 31 (in millions) 2024 2023 At actual currency rates At constant currency rates 1 Care and Connectivity Solutions $ 1,814 $ 1,800 1 % 1 % Front Line Care 1,137 1,213 (6) % (6) % Total Healthcare Systems & Technologies net sales $ 2,951 $ 3,013 (2) % (2) %
Read the annual filing ↗

TMCI Core

Annual filing released 2025-02-27 · GPT 6 Luna

We are a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. We have pioneered and patented the Lapiplasty® 3D Bunion Correction System®—a combination of instruments, implants and surgical methods designed to surgically correct all three planes of the bunion deformity and address the root cause of the bunion, helping patients get back to their active lifestyles. To further support the needs of bunion patients, we have introduced our Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot.
Segments The Company is a single reportable segment entity, which is in the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. The Company's chief executive officer is the chief operating decision maker ("CODM"). The CODM regularly reviews entity-wide net income and operating results compared to budget and forecast information to assess the Company's performance and to allocate resources for its single reporting segment. The measure of profit or loss is reported in the Statement of Operations and Comprehensive Loss. The measure of segment assets is reported on the Company's Balance Sheet. The Company does not have any intra-entity sales or transfers. All long-lived assets are maintained in the United States.
Read the annual filing ↗

Technology

BAX Core

Annual filing released 2025-02-21 · GPT 6 Luna

EXECUTIVE OVERVIEW Description of the Company, Recent Strategic Actions and Business Segments Baxter International Inc. is a global medical technology with approximately 38,000 employees worldwide who are engaged in the development, manufacture and sale of a broad range of products, digital health solutions and therapies used by hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices and patients at home under physician supervision. Our global footprint and the critical nature of our products and services, which are sold in over 100 countries as of December 31, 2024, after giving effect to the Kidney Care sale, play a key role in expanding access to healthcare in emerging and developed countries. In mid-2022, our Board of Directors authorized a strategic review of our business portfolio, with the goal of increasing stockholder value.
Under this operating model, our business is currently comprised of three reportable segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. Our segments were changed during the third quarter of 2023 to align with our new operating model. The Medical Products & Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products. The Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health 35
Read the annual filing ↗

TMCI Material

Annual filing released 2025-02-27 · GPT 6 Luna

We are a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. We have pioneered and patented the Lapiplasty® 3D Bunion Correction System®—a combination of instruments, implants and surgical methods designed to surgically correct all three planes of the bunion deformity and address the root cause of the bunion, helping patients get back to their active lifestyles. To further support the needs of bunion patients, we have introduced our Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot.
For Adductoplasty Procedures in which fusion is performed on multiple TMT joints, either CPT 28730 or CPT 28735 applies, both of which are classified under APC 5115. For the Nanoplasty and Percuplasty Procedures, CPT 28306 applies. For MTP fusions using the SpeedMTP implant or our other plates, CPT 28750 applies. Components of Our Results of Operations Revenue We currently generate revenue from the sale of our implant kit systems, single-use sterile instruments, and other complementary products. Our systems bring together single-use implant kits, reusable instrument trays, and surgical techniques. We sell the kits and single-use instruments and other products to physicians, surgeons, hospitals and ambulatory surgery centers in the United States through a network of employee sales representatives and independent sales agencies.
Read the annual filing ↗

Hardware

BAX Material

Annual filing released 2025-02-21 · GPT 6 Luna

The Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including surgical video technologies, precision positioning devices and other accessories.
Healthcare Systems & Technologies Our Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including surgical video technologies, precision positioning devices and other accessories. Percent change years ended December 31 (in millions) 2024 2023 At actual currency rates At constant currency rates 1 Care and Connectivity Solutions $ 1,814 $ 1,800 1 % 1 % Front Line Care 1,137 1,213 (6) % (6) % Total Healthcare Systems & Technologies net sales $ 2,951 $ 3,013 (2) % (2) %
Read the annual filing ↗

TMCI Not tagged

Annual filing released 2025-02-27 · GPT 6 Luna

This activity has no positive tag in the selected filing snapshot.

Read the annual filing ↗

Manufacturing

BAX Core

Annual filing released 2025-02-21 · GPT 6 Luna

As of December 31, 2024, after giving effect to the recent sale of our Kidney Care business (as discussed below), we manufactured products in over 20 countries and sold them in over 100 countries. Baxter International Inc. was incorporated under Delaware law in 1931. As used in this report, “Baxter International” means Baxter International Inc. and “we", "our” or "us" means Baxter International and its consolidated subsidiaries, unless the context otherwise requires. Recent Strategic Actions In mid-2022, our Board of Directors authorized a strategic review of our business portfolio, with the goal of increasing stockholder value. As part of that review process, we identified and evaluated a range of potential strategic actions, including opportunities for sales and other separation transactions.
Segments Location Owned/Leased Medical Products & Therapies Aibonito, Puerto Rico Leased Alliston, Canada Owned Cali, Colombia Owned Cartago, Costa Rica Owned Haina, Dominican Republic Leased Hayward, California Leased Cleveland, Mississippi Leased Medina, New York Leased Jayuya, Puerto Rico Leased Sao Paulo, Brazil Owned North Cove, North Carolina Owned St. Paul, Minnesota Leased Irvine, California Owned Toongabbie, Australia Owned Lessines, Belgium Owned Marsa, Malta Leased Sabinanigo, Spain Owned San Vittore, Switzerland Leased Thetford, United Kingdom Owned Tel Aviv, Israel Leased Elstree, United Kingdom Leased Shanghai, China Owned Mountain Home, Arkansas Owned/Leased (1)
Read the annual filing ↗

TMCI Not tagged

Annual filing released 2025-02-27 · GPT 6 Luna

This activity has no positive tag in the selected filing snapshot.

Read the annual filing ↗

Pharmaceuticals

BAX Material

Annual filing released 2025-02-21 · GPT 6 Luna

The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthetics and drug compounding services. For financial information about our segments, see Note 18 in Item 8 of this Annual Report on Form 10-K. Business Strategy Our business strategy is focused on driving sustainable growth and innovation aligned with our mission to save and sustain lives and our vision to transform healthcare with a customer focus to help improve patient outcomes, enhance workflow efficiency, and enable cost-effective care. Our diversified and broad portfolio of medical products that treat acute or chronic conditions and our global presence are core components of our strategy as we work to achieve these objectives. We are focused on key strategic pillars as part of our pursuit of industry leading performance: innovation; operational efficiency;
reflecting the macroeconomic environment in 2023. Front Line Care net sales increased 6% for the year ended December 31, 2023, as compared to the prior year period, primarily driven by increased demand for our cardiology products, patient monitoring systems and physical assessment tools. Performance in the current year benefited from backlog reductions due to improved availability of component parts used in certain of our products. 40 Pharmaceuticals Our Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthetics and drug compounding services. Percent change years ended December 31 (in millions) 2024 2023 At actual currency rates At constant currency rates 1 Injectables and Anesthesia $ 1,373 $ 1,347 2 % 3 % Drug Compounding 1,038 902 15 % 15 % Total Pharmaceuticals net sales $ 2,411 $ 2,249 7 % 7 %
Read the annual filing ↗

TMCI Not tagged

Annual filing released 2025-02-27 · GPT 6 Luna

This activity has no positive tag in the selected filing snapshot.

Read the annual filing ↗
What each company does

Compare the businesses

Baxter International Inc.

BAX · XNYS

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Open BAX dashboard ↗

Treace Medical Concepts, Inc. Common Stock

TMCI · XNAS

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot. It serves physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Open TMCI dashboard ↗
Financial data

Fundamentals side by side

Explore financial charts ↑
Show fundamentals table · 11 rows, 3 columns
MetricBAXTMCI
ExchangeXNYSXNAS
SectorHealthcareHealthcare
IndustryMedical Instruments & SuppliesMedical Devices
Market observation2026-11-162026-11-16
Closing price (USD)$25.54$4.42
Market cap (USD)$13.21B$289.77M
P/E (TTM)UnavailableUnavailable
Latest annual period2025-12-312025-12-31
Revenue (annual, USD)$11.24B$212.69M
Net income (annual, USD)$-957.00M$-59.00M
Gross margin (annual)30.05%79.81%

USD values from stored observations. Fiscal period endings and availability dates may differ.

BAX period ended 2025-12-31 · available 2026-02-12 · SEC filing ↗TMCI period ended 2025-12-31 · available 2026-02-27 · SEC filing ↗

Related stock comparisons

Browse all BAX comparisons ↗ · Browse all TMCI comparisons ↗

Behind the comparison

Sources and methodology

Price return uses split-adjusted daily closes and excludes dividends. Both stocks start on the first shared trading day within the selected window. Unavailable metrics leave gaps.

Financials use SEC canonical statements available by the displayed cutoff, retaining each company's fiscal period end. Annual and quarterly amounts are shown separately. P/E is unavailable when earnings do not support a positive ratio.

Business overlap uses industry tags from annual filings released in 2025. Each core activity receives full weight; each material activity receives one quarter of that weight. Rarer industries carry more weight. We sum the smaller exposure for each shared activity and divide it by the sum of the larger exposure for every activity in either company. This measures business overlap, rather than price correlation or expected returns.

Search eligibility requires distinct issuers, a shared core category and at least 20% weighted overlap, supported by industry or sector evidence and specific business activities. Broad classifications require stronger overlap within the same sector. Comparisons also need at least 252 shared price observations within two years, recent trading and a common sourced revenue or net-income trend. Missing P/E or gross margin alone does not exclude a comparison. The eligibility snapshot refreshes daily. Related comparisons use a separate, stricter peer rule; their ten-peer discovery limit does not limit search eligibility. Other stock pairs remain available in the comparison tool.

Statements available through 2026-11-17. Industry snapshot: 2025-12-31 · 5,721 classified issuers.

Opening chat…

Preparing your conversation.